Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).
暂无分享,去创建一个
R. Motzer | T. Powles | T. Choueiri | S. Park | B. Escudier | D. George | C. Kollmannsberger | S. Pal | S. Rha | E. Grande | C. Suarez | H. Gurney | P. Geertsen | J. Pikiel | A. Arroyo | Mark Dean | M. Gross‐Goupil